Founded in 1994, Genesis is a New Zealand-based biotechnology company. It has built a broad therapeutic development platform targeting immune disorders and cancer and is focusing on developing RNAi therapeutics. The company has an extensive patent portfolio.

AgriGenesis, a wholly owned subsidiary of Genesis, has been developing technologies to grow shrubby Salix (willow) and produce valuable biofuels and biomaterials including ethanol, xylose and unsulfonated lignin. AgriGenesis plans to transfer this programme to Biojoule Technologies Ltd which is seeking to raise new capital and government investment to support the ongoing development of the programme.